ASCO 2015: new info, summary, etc
Ok here we go:
Average age so far treated is 63 t /- 9 years. But you know, if you add 9 to 63 you do not get the age of the oldest person, which was 85, and if you subtract 9, you do not get the youngest person, aged 42. I have always said that there are lies and damned lies, and statistics.
Next up- trial subjects 26 females and 14 males: that is awfully close to 2:1, isn't it? But not quite, right? Because 2:1 would be 28 to 14 and that is not on the poster. Let's stick to the facts. OK??!? OK.
Cancer types : I believe someone has already done the math here. By that I mean, someone has gone through each of the 40 subjects, and added up the cancer types, which is a real service to the board. Can we agree on that? I always find a neat tidy summary, reflecting minutes of unnecessary work, to be helpful. Someone already did that.
So instead, moving right along, let's summarize the cohort dosing data:
3 subjects received doses of 450mg/m2, and
8 subjects received doses of 350mg/m2, and
a lot of other people, roughly 40-11, you do the math, received less
Next biomarkers.
OK I keep hearing about the 48%. That is the percent of 31 subjects who had increases in p21.
But, what is underreported is that 52% of patients had a less than 10% response to Kevetrin More than half had no response? Was that on the poster? It was. Were those the patients in the early cohorts? Maybe, but watch out: you try to put any information on an ASCO poster and you will be toast. Unless it is a tidbit that someone went up by 205% That's a lot, right? It is a lot. More than 200% is...oh yeah more than doubled. Although 205% and 200% are very similar. At any rate it is a big increase and someone snuck this data point right under those ASCO noses. Am I right?
Next ,the summary ( and this is very grand , I can assure you):
Here I would very much like to present a 1, and a 2, and a 3, and maybe even a 4, of the very simplest facts about the mechanism of action of Kevetrin. These facts would be known by you had you paid even the slightest bit of attention to any prior CTIX press releases abut Kevetrin or to the 2013 poster, to cite just one easy example. These very same facts are repeated in the ASCO poster under the SUMMARY, and then they are endlessly repeated by a variety of posters, on this board, as new information. They refer to hiphoptosis and degraded mutants, among other sordid topics. I cannot repeat them here, even though many of you you find the repetition of very old p53 mechanisms of action to be soothing.
OK so there you have it. next topic: CEO update of the the days old poster...to be continued.
